Orthocell Appoints Thailand Distributor for Remplir
Filed with ASX · · 3 pages · English
Summary by 6ix AI
MediTime's established network and expertise in orthopaedics will support the adoption of Remplir among surgeons in Thailand. The appointment follows regulatory approval from the Thai FDA for Remplir's commercialization in the country.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Orthocell
- Remplir™: Australian Nerve Repair Device Supports Victims of War in Ukraine
- First Sales of Remplir Achieved in US$75m Canadian Market
- Compelling 90% Success Rate for Remplir in Real World Study
- Q3 FY26 Investor Presentation
- First Surgical Use of Remplir in US Department of Defense
Later from Orthocell
- Q4 FY26 ASX Investor Presentation
- Orthocell Achieves First Remplir Sales in Thailand
- Remplir Shows Excellent Early Prostatectomy Results
- Quarterly Activity Report & Appendix 4C
- Q1 FY27 OCC Investor Presentation
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell